Management of transfusion-dependent β-thalassemia (TDT): Expert insights and practical overview from the Middle East

Amal El-Beshlawy; Hany Dewedar; Salwa Hindawi; Salam Alkindi; Azza A. Tantawy; Mohamed A. Yassin; Ali T. Taher

doi:10.1016/j.blre.2023.101138

Management of transfusion-dependent β-thalassemia (TDT): Expert insights and practical overview from the Middle East

Amal El-Beshlawy, Hany Dewedar, Salwa Hindawi, Salam Alkindi, Azza A. Tantawy, Mohamed A. Yassin, Ali T. Taher^*

^*Corresponding author for this work

Haematology

Research output: Contribution to journal › Review article › peer-review

Abstract

β-Thalassemia is one of the most common monogenetic diseases worldwide, with a particularly high prevalence in the Middle East region. As such, we have developed long-standing experience with disease management and devising solutions to address challenges attributed to resource limitations. The region has also participated in the majority of clinical trials and development programs of iron chelators and more novel ineffective erythropoiesis-targeted therapy. In this review, we provide a practical overview of management for patients with transfusion-dependent β-thalassemia, primarily driven by such experiences, with the aim of transferring knowledge to colleagues in other regions facing similar challenges.

Original language	English
Article number	101138
Journal	Blood Reviews
DOIs	https://doi.org/10.1016/j.blre.2023.101138
Publication status	Published - Oct 1 2023

Keywords

Complications
Management
Thalassemia
Transfusion
iron chelation

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1016/j.blre.2023.101138

Cite this

@article{7d973b6348fb41d4960bfd1c9b0f77e9,

title = "Management of transfusion-dependent β-thalassemia (TDT): Expert insights and practical overview from the Middle East",

abstract = "β-Thalassemia is one of the most common monogenetic diseases worldwide, with a particularly high prevalence in the Middle East region. As such, we have developed long-standing experience with disease management and devising solutions to address challenges attributed to resource limitations. The region has also participated in the majority of clinical trials and development programs of iron chelators and more novel ineffective erythropoiesis-targeted therapy. In this review, we provide a practical overview of management for patients with transfusion-dependent β-thalassemia, primarily driven by such experiences, with the aim of transferring knowledge to colleagues in other regions facing similar challenges.",

keywords = "Complications, Management, Thalassemia, Transfusion, iron chelation",

author = "Amal El-Beshlawy and Hany Dewedar and Salwa Hindawi and Salam Alkindi and Tantawy, {Azza A.} and Yassin, {Mohamed A.} and Taher, {Ali T.}",

year = "2023",

month = oct,

day = "1",

doi = "10.1016/j.blre.2023.101138",

language = "English",

journal = "Blood Reviews",

issn = "0268-960X",

publisher = "Churchill Livingstone",

}

TY - JOUR

T1 - Management of transfusion-dependent β-thalassemia (TDT)

T2 - Expert insights and practical overview from the Middle East

AU - El-Beshlawy, Amal

AU - Dewedar, Hany

AU - Hindawi, Salwa

AU - Alkindi, Salam

AU - Tantawy, Azza A.

AU - Yassin, Mohamed A.

AU - Taher, Ali T.

PY - 2023/10/1

Y1 - 2023/10/1

N2 - β-Thalassemia is one of the most common monogenetic diseases worldwide, with a particularly high prevalence in the Middle East region. As such, we have developed long-standing experience with disease management and devising solutions to address challenges attributed to resource limitations. The region has also participated in the majority of clinical trials and development programs of iron chelators and more novel ineffective erythropoiesis-targeted therapy. In this review, we provide a practical overview of management for patients with transfusion-dependent β-thalassemia, primarily driven by such experiences, with the aim of transferring knowledge to colleagues in other regions facing similar challenges.

AB - β-Thalassemia is one of the most common monogenetic diseases worldwide, with a particularly high prevalence in the Middle East region. As such, we have developed long-standing experience with disease management and devising solutions to address challenges attributed to resource limitations. The region has also participated in the majority of clinical trials and development programs of iron chelators and more novel ineffective erythropoiesis-targeted therapy. In this review, we provide a practical overview of management for patients with transfusion-dependent β-thalassemia, primarily driven by such experiences, with the aim of transferring knowledge to colleagues in other regions facing similar challenges.

KW - Complications

KW - Management

KW - Thalassemia

KW - Transfusion

KW - iron chelation

UR - http://www.scopus.com/inward/record.url?scp=85174699366&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85174699366&partnerID=8YFLogxK

UR - https://www.mendeley.com/catalogue/3299cbed-7fa2-30fd-9e03-2f59845e40ed/

U2 - 10.1016/j.blre.2023.101138

DO - 10.1016/j.blre.2023.101138

M3 - Review article

C2 - 37867006

AN - SCOPUS:85174699366

SN - 0268-960X

JO - Blood Reviews

JF - Blood Reviews

M1 - 101138

ER -

Management of transfusion-dependent β-thalassemia (TDT): Expert insights and practical overview from the Middle East

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this